title: Complete regression of experimental prostate cancer in nude mice by repeated hyperthermia using magnetite cationic liposomes and a newly developed solenoid containing a ferrite core.
abstract: BACKGROUND
  Magnetite cationic liposomes (MCLs) can be used to induce hyperthermia because they generate heat in an alternating magnetic field (AMF). This study aimed at developing more practical method for MCL hyperthermia examining the effect of MCL-induced hyperthermia on human prostate cancer in vivo.
  
  
  METHODS
  A newly developed AMF generator incorporating a solenoid with a ferrite core (FC) was used. Human prostate cancer cells (PC-3 and LNCap) were injected subcutaneously into nude mice. MCLs were injected into tumor nodule and the mice were exposed into AMF three times at 24-hr intervals (repeated hyperthermia; RH) until complete tumor regression was observed.
  
  
  RESULTS
  Irradiation with an AMF generated by newly developed device can adequately increase the temperature of tumor tissue. Frequent RH resulted in complete tumor regression in all nude mice.
  
  
  CONCLUSIONS
  RH using MCLs may be a promising new therapy for hormone-refractory human prostate cancer in the future.
authors.affiliation: Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. norikawa@med.nagoya-cu.ac.jp
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Kawai
authors.forename: Akira
authors.initials: A
authors.lastname: Ito
authors.forename: Yoko
authors.initials: Y
authors.lastname: Nakahara
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Honda
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Futakuchi
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Shirai
authors.forename: Keiichi
authors.initials: K
authors.lastname: Tozawa
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kohri
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy; D052203:Ferrosoferric Oxide / Q000008:administration & dosage / Q000627:therapeutic use*; D006979:Hyperthermia, Induced; D007202:Indicators and Reagents / Q000008:administration & dosage / Q000627:therapeutic use*; D007501:Iron / Q000008:administration & dosage / Q000627:therapeutic use; D008081:Liposomes; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D011471:Prostatic Neoplasms / Q000628:therapy* / Q000662:veterinary; D013696:Temperature; D016896:Treatment Outcome
chemical_list: D007202:Indicators and Reagents; D008081:Liposomes; D007501:Iron; D052203:Ferrosoferric Oxide